Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

Winquist, Eric; Ernst, D. Scott; Jonker, D.; Moore, Malcolm J.; Segal, Roanne; Lockwood, G.; Rodgers, A.

doi:10.1016/s0959-8049(03)00358-7

Cited by 19 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its liposomal formulation allows the selective accumulation in the tumours, providing an increased exposure of cancer cells to the free drug form [7]. LDox has shown activity against urothelial tumours in clinical trials [12]. The concurrent administration of LDox with radiotherapy has been previously examined in head-neck, lung and breast cancer [7,13], showing an excellent tolerance profile.…”

Section: Discussionmentioning

confidence: 99%

Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)

et al. 2010

View full text Add to dashboard Cite

Cisplatin-based radio-chemotherapy is an effective alternative to cystectomy. The position of cisplatin has been challenged by novel drugs, while altered radiotherapy fractionation is also tested against conventional radiotherapy (RT). This study focuses on liposomal doxorubicin (LDox) in combination with an aggressive radiotherapy scheme (HypoARC). Eighty-two bladder cancer patients were treated with hypofractionated/accelerated RT (14×2.7 Gy to the pelvis and 15×3.4 Gy to the bladder, within 19 days), supported with amifostine (0-1,000 mg sc.). Forty-one out of 82 patients received concurrently LDox (20 mg/m2 for 3 bi-weekly cycles). LDox was free of haematological toxicity, erythordysestesia grade 1 being the only side effect noted in 5/41 patients. Although the incidence of early toxicities did not increase with LDox, delays of radiotherapy were increased (P=0.16). Amifostine significantly protected patients against toxicities and delays. There were no severe late complications recorded. Complete response rate was similar in both groups (85.4 vs. 87.8%). The 3-year local relapse-free survival was better in patients receiving LDox, but at a non-statistical level (64 vs. 47%; P=0.59). The 3-year survival rate was significantly improved in T2-4 stage patients receiving LDox (72.1 vs. 58.7%; P=0.04). Multivariate analysis did not identify any independent prognostic variables of relapse or death events. LDox is a well-tolerated drug during pelvic radiotherapy. Although its efficacy in terms of bladder tumour control rates could not be substantiated due to the high efficacy of the HypoARC regimen applied, survival was improved suggesting either a spatial co-operation or a radio-sensitization of pelvic in-field subclinical disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)

et al. 2010

View full text Add to dashboard Cite

show abstract

“…This makes a case for the addition of or substitution with pegylated liposomal formulation of doxorubicin in the treatment of upper tract TCCs. [23]…”

Section: Treatment Of Genitourinary Cancermentioning

confidence: 99%

Nanotechnology in Urology

Jayasimha

2017

Indian J Urol

View full text Add to dashboard Cite

Introduction:Nanotechnology has revolutionized our approach to medical diagnostics as well as therapeutics and has spanned an entirely new branch of research. This review addresses the potential applications of Nanotechnology in Urology. This article is based on the Dr. Sitharaman Best Essay award of the Urological Society of India for 2016.Methods:A PubMed search was performed for all relevant articles using the terms, “nanotechnology, nanoparticles, nanoshells, nanoscaffolds, and nanofibers.”Results:The developments in diagnostics include novel techniques of imaging of genitourinary malignancies, prostate-specific antigen measurement, early detection of mutations that are diagnostic for polycystic kidney disease. The potential applications of nanotechnology are in the targeted therapy of genitourinary malignancies, erectile dysfunction, overactive bladder, bladder reconstruction, construction of artificial kidneys and biodegradable stents as well as in robotic surgery.Conclusions:Nanotechnology is a rapidly emerging branch of research in urology with diverse and clinically significant applications in diagnostics as well as therapeutics.

show abstract

“…Similarly, Winquist et al. looked at i.v. pegylated‐liposomal doxorubicin to treat metastatic unresectable TCC (of bladder or upper tract origin) in a phase II trial of 34 patients.…”

Section: Drug Deliverymentioning

confidence: 99%

Nanotechnology applications in urology: a review

et al. 2014

View full text Add to dashboard Cite

The objectives of this review are to discuss the current literature and summarise some of the promising areas with which nanotechnology may improve urological care. A Medline literature search was performed to elucidate all relevant studies of nanotechnology with specific attention to its application in urology. Urological applications of nanotechnology include its use in medical imaging, gene therapy, drug delivery, and photothermal ablation of tumours. In vitro and animal studies have shown initial encouraging results. Further study of nanotechnology for urological applications is warranted to bridge the gap between preclinical studies and translation into clinical practice, but nanomedicine has shown significant potential to improve urological patient care.

show abstract

Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

Cited by 19 publications

References 27 publications

Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)

Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC)

Nanotechnology in Urology

Nanotechnology applications in urology: a review

Contact Info

Product

Resources

About